RTOG 0525 Phase III trial comparing conventional adjuvant Temazolomide with dose-intensive Temazolomide in patients with newly diagnosed glioblastoma

Description: 
The goal of this study is to further investigate the clinical efficacy and safety of two doses of the chemotherapy temazolomide.  This drug has shown benefit in treating glioblastoma when combined with radiation. This study seeks to determine if intensifying the dose of temazolomide enhances treatment including overall survival.

Design:
A prospective, randomized, double-blind, multicenter, parallel group, enrolling newly diagnosed patients with glioblastoma.  Enrollment period is projected to be 2 years.  Target number of patients nationally is a total of 850.

Eligibility: 
Male and Female patients between over 18 years of age with a new diagnosis of glioblastoma by surgical biopsy. Patients must begin treatment within 5 weeks of neurosurgery

Sponsor:
Radiation Therapy Oncology Group

Contact:
Lara Kunschner, MD (Co-Investigator), David Parda, MD (Radiation PI), Judy Negley RN 

A Prospective, Multi-center Trial of NovoTTF-100A compared to Best Standard of Care in Patients with Progressive or Recurrent GBM

Description:
This study will test the effectiveness of a new approach to control the growth of glioblastoma once after recurrence following initial chemotherapy and radiation. The new approach utilizes a unique technology after conventional chemotherapy and radiation fails.

Design:
Phase II, multi-center trial.

Eligibility: 
Eligible patients will be at least 18 years old, and have recurrent Glioblastoma.

Sponsor:
Novocure

Contact:
Lara Kunschner, MD (PI), Phyllis Wanetick, RN and Tracey Stevens RN (Research Coordinators) 412.359.8848